Examples of 'crizotinib' in a sentence
Meaning of "crizotinib"
'Crizotinib' as a noun is a medication used in the treatment of certain types of cancer
Show more definitions
- An aminopyridine drug used to treat certain kinds of lung carcinoma.
How to use "crizotinib" in a sentence
Basic
Advanced
crizotinib
There are no data in pregnant women using crizotinib.
Carcinogenicity studies with crizotinib have not been performed.
All patients were treated with prior crizotinib.
Crizotinib was not shown to be teratogenic in pregnant rats or rabbits.
All patients had received previous crizotinib.
Agents that may decrease crizotinib plasma concentrations.
It is indicated in patients previously treated with crizotinib.
Agents that may increase crizotinib plasma concentrations.
Crizotinib is extensively metabolized in the liver.
Agents whose plasma concentrations may be altered by crizotinib.
Crizotinib should be discontinued in patients who develop gastrointestinal perforation.
The activity of this fusion gene is inhibited by crizotinib.
Crizotinib has not been studied in patients with hepatic impairment.
Xalkori is a medicine that contains the active substance crizotinib.
Crizotinib resulted in symptoms benefit by significantly prolonging time to deterioration median.
See also
Indication for crizotinib.
It is not known whether crizotinib and its metabolites are excreted in human milk.
Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers.
A decision to resume crizotinib should consider the potential benefit to the patient.
Avoid grapefruit or grapefruit juice which may increase plasma concentrations of crizotinib.
The safety and efficacy of crizotinib in paediatric patients has not been established.
Tumors from individual animal were harvested when they became resistant to crizotinib.
Close clinical surveillance is recommended when crizotinib is administered with these medicinal products.
Health Canada will continue to monitor the safety of crizotinib.
Crizotinib and at least one other ALK TKI.
The results of an in vitro phototoxicity study demonstrated that crizotinib may have phototoxic potential.
However, crizotinib showed no improvement on overall survival compared to chemotherapy.
The active substance in XALKORI is crizotinib.
However, crizotinib has not been studied in patients with hepatic impairment.
No Danish ADR reports of cardiac failure associated with crizotinib.
Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease.
This can be blocked by the lung cancer medicine, called crizotinib.
Crizotinib treatment should be withheld if ILD / pneumonitis is suspected.
Medicines called kinase inhibitors for treatment of other cancers - crizotinib or imatinib.
In vitro, crizotinib is not an inhibitor of BSEP at clinically relevant concentrations.
In clinical studies, prolonged QT interval was observed with crizotinib.
Crizotinib was not mutagenic in vitro in the bacterial reverse mutation ( Ames ) assay.
Humanized anti-HGF mAb Crizotinib is now on the market in some countries.
Crizotinib blocks growth-promoting messages through the ALK signaling pathway.
Caution is therefore recommended in case of coadministration of crizotinib with moderate CYP3A inhibitors.
Coadministration of crizotinib with strong CYP3A inhibitors may increase crizotinib plasma concentrations.
Inhibitors ; or - you have been previously treated with crizotinib followed by another ALK inhibitor.
Coadministration of crizotinib with strong CYP3A inhibitors is expected to increase crizotinib plasma concentrations.
Alunbrig was effective in treating patients with ALK-positive NSCLC previously treated with crizotinib.
Crizotinib is approved for patients with ROS1 mutations.
Previous Previous post, Bronchial carcinoma, Added benefit of crizotinib not proven.
Crizotinib has also shown efficacy in treatment of NSCLC with ROS1 translocations.
Re-treatment with crizotinib.
Crizotinib is used to stop proteins from being made by the ALK and ROS1 gene.
All-causality bradycardia was reported in clinical studies in 13 % of patients treated with crizotinib.
